Pages that link to "Q31116328"

The following pages link to Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors (Q31116328):

Displaying 36 items.

• The dopamine metabolite 3-methoxytyramine is a neuromodulator (Q21091097) (← links)
• Selective noradrenaline reuptake inhibitors for schizophrenia (Q24197825) (← links)
• The role of the catechol-O-methyltransferase (COMT) gene in personality and related psychopathological disorders (Q26863407) (← links)
• COMT val158met moderation of dopaminergic drug effects on cognitive function: a critical review (Q28074860) (← links)
• Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism (Q28282922) (← links)
• Opposite effects of tolcapone on amphetamine-disrupted startle gating in low vs. high COMT-expressing rat strains (Q30439281) (← links)
• Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia (Q30489404) (← links)
• Neuroimaging and molecular genetics of schizophrenia: pathophysiological advances and therapeutic potential. (Q31142672) (← links)
• Treatment of cognitive deficits in schizophrenia. Part 2: Pharmacological strategies (Q33535963) (← links)
• A hotspot of inactivation: The A22S and V108M polymorphisms individually destabilize the active site structure of catechol O-methyltransferase (Q34005767) (← links)
• Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy (Q34147129) (← links)
• Systematic of psychiatric disorders between categorical and dimensional approaches: Kraepelin's dichotomy and beyond (Q34783420) (← links)
• A dual-tracer study of extrastriatal 6-[18F]fluoro-m-tyrosine and 6-[18F]-fluoro-L-dopa uptake in Parkinson's disease. (Q34825634) (← links)
• Effect of polymorphisms of three genes mediating monoamine signalling on brain morphometry in schizophrenia and healthy subjects (Q35579193) (← links)
• From an executive network to executive control: a computational model of the n-back task. (Q35716765) (← links)
• Effects of quetiapine and sertindole on subchronic ketamine-induced deficits in attentional set-shifting in rats (Q35748684) (← links)
• COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition (Q35859549) (← links)
• Interaction between COMT rs5993883 and second generation antipsychotics is linked to decreases in verbal cognition and cognitive control in bipolar disorder (Q35978132) (← links)
• COMT val158met polymorphism and molecular alterations in the human dorsolateral prefrontal cortex: Differences in controls and in schizophrenia (Q36813596) (← links)
• The forthcoming revision of the diagnostic and classificatory system: perspectives based on the European psychiatric tradition (Q37317846) (← links)
• Genes, cognition and brain through a COMT lens (Q37384503) (← links)
• To What Extent Do Neurobiological Sleep-Waking Processes Support Psychoanalysis? (Q37792548) (← links)
• The texture of the real: experimentation and experience in schizophrenia (Q38499326) (← links)
• The link between schizophrenia and substance use disorder: A unifying hypothesis (Q38729376) (← links)
• Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia. (Q38762256) (← links)
• Characterization of non-nitrocatechol pan and isoform specific catechol-O-methyltransferase inhibitors and substrates (Q41777494) (← links)
• Brain catechol-O-methyltransferase (COMT) inhibition by tolcapone counteracts recognition memory deficits in normal and chronic phencyclidine-treated rats and in COMT-Val transgenic mice (Q42429830) (← links)
• Tolcapone enhances food-evoked dopamine efflux and executive memory processes mediated by the rat prefrontal cortex (Q45776671) (← links)
• Introduction: genes, cognition and neuropsychiatry. (Q45919191) (← links)
• Tolcapone-Enhanced Neurocognition in Healthy Adults: Neural Basis and Predictors (Q46300567) (← links)
• Does COMT val158met affect behavioral phenotypes: yes, no, maybe? (Q46314685) (← links)
• Selective noradrenaline reuptake inhibitors for schizophrenia. (Q47552058) (← links)
• [In memory of Lev L'vovich Kiselev]. (Q51960839) (← links)
• Association of functional COMT Val108/Met polymorphism with smoking cessation in a nicotine replacement therapy. (Q54305284) (← links)
• Targeting Metalloenzymes for Therapeutic Intervention (Q59830619) (← links)
• Systems pharmacogenomics - gene, disease, drug and placebo interactions: a case study in COMT (Q92263838) (← links)